{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:35:29Z","timestamp":1794026129933,"version":"4.8.0"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":531,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Heart failure with preserved ejection fraction (HFpEF) is associated with an array of central and peripheral haemodynamic and metabolic changes. The exact pathogenesis of exercise limitation in HFpEF remains uncertain. Our aim was to compare lactate accumulation and central haemodynamic responses to exercise in patients with HFpEF, non-cardiac dyspnoea (NCD), and healthy volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Right heart catheterization with mixed venous blood gas and lactate measurements was performed at rest and during symptom-limited supine exercise. Multivariable analyses were conducted to determine the relationship between haemodynamic and biochemical parameters and their association with exercise capacity. Of 362 subjects, 198 (55%) had HFpEF, 103 (28%) had NCD, and 61 (17%) were healthy volunteers. This included 139 (70%) females with HFpEF, 77 (75%) in NCD (P = 0.41 HFpEF vs. NCD), and 31 (51%) in healthy volunteers (P &amp;lt; 0.001 HFpEF vs. volunteers). The median age was 71 (65, 75) years in HFpEF, 66 (57, 72) years in NCD, and 49 (38, 65) years in healthy volunteers (HFpEF vs. NCD or volunteer, both P &amp;lt; 0.001). Peak workload was lower in HFpEF compared with healthy volunteers [52 W (interquartile range 31\u201373), 150 W (125\u2013175), P &amp;lt; 0.001], but not NCD [53 W (33, 75), P = 0.85]. Exercise lactate indexed to workload was higher in HFpEF at 0.08 mmol\/L\/W (0.05\u20130.11), 0.06 mmol\/L\/W (0.05\u20130.08; P = 0.016) in NCD, and 0.04 mmol\/L\/W (0.03\u20130.05; P &amp;lt; 0.001) in volunteers. Exercise cardiac index was 4.5 L\/min\/m2 (3.7\u20135.5) in HFpEF, 5.2 L\/min\/m2 (4.3\u20136.2; P &amp;lt; 0.001) in NCD, and 9.1 L\/min\/m2 (8.0\u20139.9; P &amp;lt; 0.001) in volunteers. Oxygen delivery in HFpEF was lower at 1553 mL\/min (1175\u20131986) vs. 1758 mL\/min (1361\u20132282; P = 0.024) in NCD and 3117 mL\/min (2667\u20133502; P &amp;lt; 0.001) in the volunteer group during exercise. Predictors of higher exercise lactate levels in HFpEF following adjustment included female sex and chronic kidney disease (both P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HFpEF is associated with reduced exercise capacity secondary to both central and peripheral factors that alter oxygen utilization. This results in hyperlactataemia. In HFpEF, plasma lactate responses to exercise may be a marker of haemodynamic and cardiometabolic derangements and represent an important target for future potential therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14794","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:39:10Z","timestamp":1714696750000},"page":"2557-2565","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hyperlactataemia is a Marker of Reduced Exercise Capacity in Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2728-7526","authenticated-orcid":false,"given":"Emilia","family":"Nan Tie","sequence":"first","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , Melbourne, VIC, 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Wolsk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev-Gentofte Hospital , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Nanayakkara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , Melbourne, VIC, 3004 ,","place":["Australia"]},{"name":"Baker Heart and Diabetes Institute , Melbourne ,","place":["Australia"]},{"name":"Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Vizi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , Melbourne, VIC, 3004 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Mariani","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , Melbourne, VIC, 3004 ,","place":["Australia"]},{"name":"Baker Heart and Diabetes Institute , Melbourne ,","place":["Australia"]},{"name":"Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob Eifer","family":"Moller","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Cardiology, Odense University Hospital , Odense ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hassager","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Alfred Hospital , Melbourne, VIC, 3004 ,","place":["Australia"]},{"name":"Baker Heart and Diabetes Institute , Melbourne ,","place":["Australia"]},{"name":"Monash University , Melbourne ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2026012113131426000_ehf214794-bib-0001","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2026012113131426000_ehf214794-bib-0002","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026012113131426000_ehf214794-bib-0003","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJMc2000284","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. Reply","volume":"382","author":"Solomon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113131426000_ehf214794-bib-0004","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jchf.2021.11.006","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012113131426000_ehf214794-bib-0005","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113131426000_ehf214794-bib-0006","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"key":"2026012113131426000_ehf214794-bib-0007","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/eurheartj\/ehy301","article-title":"Heart failure with preserved ejection fraction: From mechanisms to therapies","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012113131426000_ehf214794-bib-0008","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1161\/CIRCHEARTFAILURE.109.930701","article-title":"Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction","volume":"3","author":"Borlaug","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026012113131426000_ehf214794-bib-0009","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jchf.2016.10.012","article-title":"The influence of age on hemodynamic parameters during rest and exercise in healthy individuals","volume":"5","author":"Wolsk","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026012113131426000_ehf214794-bib-0010","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jacc.2010.04.040","article-title":"Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction","volume":"56","author":"Maeder","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012113131426000_ehf214794-bib-0011","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.106.632745","article-title":"Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction","volume":"114","author":"Borlaug","year":"2006","journal-title":"Circulation"},{"key":"2026012113131426000_ehf214794-bib-0012","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ejhf.2146","article-title":"Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction","volume":"23","author":"Wolsk","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012113131426000_ehf214794-bib-0013","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.amjcard.2013.12.031","article-title":"Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction","volume":"113","author":"Haykowsky","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026012113131426000_ehf214794-bib-0014","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jchf.2016.03.011","article-title":"Skeletal muscle mitochondrial content, oxidative capacity, and Mfn2 expression are reduced in older patients with heart failure and preserved ejection fraction and are related to exercise intolerance","volume":"4","author":"Molina","year":"2016","journal-title":"JACC Heart Fail"},{"key":"2026012113131426000_ehf214794-bib-0015","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/eurjhf\/hfr133","article-title":"Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction","volume":"13","author":"Bhella","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026012113131426000_ehf214794-bib-0016","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1161\/CIRCRESAHA.120.317933","article-title":"Targeting mitochondria-inflammation circuit by \u03b2-hydroxybutyrate mitigates HFpEF","volume":"128","author":"Deng","year":"2021","journal-title":"Circ Res"},{"key":"2026012113131426000_ehf214794-bib-0017","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1113\/JP279963","article-title":"The anaerobic threshold: 50+ years of controversy","volume":"599","author":"Poole","year":"2021","journal-title":"J Physiol"},{"key":"2026012113131426000_ehf214794-bib-0018","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1113\/jphysiol.2009.178350","article-title":"Cell-cell and intracellular lactate shuttles","volume":"587","author":"Brooks","year":"2009","journal-title":"J Physiol"},{"key":"2026012113131426000_ehf214794-bib-0019","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1249\/00005768-199108000-00006","article-title":"Myocardial lactate metabolism during exercise","volume":"23","author":"Stanley","year":"1991","journal-title":"Med Sci Sports Exerc"},{"key":"2026012113131426000_ehf214794-bib-0020","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.cjca.2016.12.013","article-title":"Metabolic modulators in heart disease: Past, present, and future","volume":"33","author":"Lopaschuk","year":"2017","journal-title":"Can J Cardiol"},{"key":"2026012113131426000_ehf214794-bib-0021","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fcvm.2019.00186","article-title":"SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function","volume":"6","author":"Maejima","year":"2019","journal-title":"Front Cardiovasc Med"},{"key":"2026012113131426000_ehf214794-bib-0022","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005434","article-title":"Hemodynamic profile of patients with heart failure and preserved ejection fraction vary by age","volume":"6","author":"Nanayakkara","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026012113131426000_ehf214794-bib-0023","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jchf.2019.01.004","article-title":"Sex differences in heart failure with preserved ejection fraction pathophysiology: A detailed invasive hemodynamic and echocardiographic analysis","volume":"7","author":"Beale","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026012113131426000_ehf214794-bib-0024","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0026-0495(92)90185-d","article-title":"Insulin resistance in obesity is associated with elevated basal lactate levels and diminished lactate appearance following intravenous glucose and insulin","volume":"41","author":"Lovejoy","year":"1992","journal-title":"Metabolism"},{"key":"2026012113131426000_ehf214794-bib-0025","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","article-title":"Cardiovascular phenotype in HFpEF patients with or without diabetes: A RELAX trial ancillary study","volume":"64","author":"Lindman","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026012113131426000_ehf214794-bib-0026","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1161\/CIRCULATIONAHA.117.031394","article-title":"Response by Obokata and Borlaug to letters regarding article, \u201cEvidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction\u201d","volume":"137","author":"Obokata","year":"2018","journal-title":"Circulation"},{"key":"2026012113131426000_ehf214794-bib-0027","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.amjcard.2020.12.012","article-title":"The chronic kidney disease phenotype of HFpEF: Unique cardiac characteristics","volume":"142","author":"Kirkman","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026012113131426000_ehf214794-bib-0028","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/cc1518","article-title":"Bench-to-bedside review: Lactate and the kidney","volume":"6","author":"Bellomo","year":"2002","journal-title":"Crit Care"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/2557\/64514851\/eschf_11_5_2557.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/2557\/64514851\/eschf_11_5_2557.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:14:57Z","timestamp":1769019297000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/5\/2557\/8271125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,2]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14794","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,5,2]]},"assertion":[{"value":"2023-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}